LDS/Medical Tests/Uveal Melanoma, Chromosome 3 Monosomy, FISH, Tissue

Uveal Melanoma, Chromosome 3 Monosomy, FISH, Tissue

Uveal melanoma is the most common primary intraocular malignancy in adults and carries a high risk of metastasis, with nearly 50% of patients developing metastatic disease within 15 years. The uveal tract includes the iris, ciliary body, and choroid, with most tumors arising in the choroid. A key prognostic biomarker in uveal melanoma is monosomy of chromosome 3 (loss of one copy of chromosome 3).

Tumors with monosomy 3 are associated with a poor prognosis and high metastatic potential, especially to the liver. Chromosome 3 harbors several critical genes, including BAP1 (BRCA1-associated protein 1), a tumor suppressor gene. Loss of one allele results in reduced tumor suppressor activity, contributing to tumor progression and aggressive behavior. Fluorescence in situ hybridization (FISH) assay targeting chromosome 3 loci provides a reliable method for detecting monosomy, making it useful for both diagnosis and prognostication of uveal melanoma.

  • Confirms diagnosis in suspected uveal melanoma
  • Provides prognostic information, identifying patients at higher risk of metastasis

Positive: Detection of monosomy 3 indicates poor prognosis and increased metastatic risk in uveal melanoma.

Negative: No evidence of monosomy 3. Does not exclude the diagnosis of uveal melanoma; other molecular alterations may be involved.

Negative

Fluorescent in-situ hybridization (FISH).

Tissue, Formalin-fixed paraffin-embedded (FFTP) tumor tissue block.

Fixed tissues are stable at room temperature for long time.

BRAF gene mutation analysis, MEK1 gene mutation analysis, NRAS gene mutation analysis, c-KIT gene mutation analysis, CBC, comprehensive metabolic panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login